Special Issue "Innovations in the Management of Chronic Rhinosinusitis"

A special issue of Sinusitis (ISSN 2673-351X).

Deadline for manuscript submissions: closed (31 May 2023) | Viewed by 1537

Special Issue Editor

Department of Surgery, University of Auckland, Auckland, New Zealand
Interests: rhinosinusitis; endoscopic sinus surgery; outcome studies; Clinical Trials; patient related outcome measurement
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chronic rhinosinusitis (CRS) is highly prevalent and has been shown to produce a significant burden to society and healthcare. Despite this, there is much that is not known about its optimum treatment. Although there are a handful of randomized trials investigating the role of medical treatments, such as antibiotics and corticosteroids, much remains unknown about formulations, dosings, treatment durations, and suitable CRS endotypes for their use.

The optimum surgical management of CRS is even less well understood with such fundamental questions as when to provide limited versus more extensive surgery still debated. Practices vary with regard to the peri-operative use of analgesia and other medications, debridements, and topical treatments, with little evidence to guide clinicians.

For this Special Issue we welcome submissions, both original research and review articles, that address any aspects of how to optimise the care of CRS patients.

Dr. Andrew J. Wood
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sinusitis is an international peer-reviewed open access semiannually journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Chronic rhinosinusitis (CRS)
  • endoscopic sinus surgery
  • management
  • treatments

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


The Safety of Topical and Intravenous Tranexamic Acid in Endoscopic Sinus Surgery
Sinusitis 2022, 6(2), 56-65; https://doi.org/10.3390/sinusitis6020008 - 18 Oct 2022
Viewed by 1254
Tranexamic acid (TXA) is an inexpensive and widely used medication indicated for the reduction of bleeding. There are data showing the efficacy of intravenous (IV) and topical TXA in endoscopic sinus surgery (ESS) but the safety of this practice is not well studied. [...] Read more.
Tranexamic acid (TXA) is an inexpensive and widely used medication indicated for the reduction of bleeding. There are data showing the efficacy of intravenous (IV) and topical TXA in endoscopic sinus surgery (ESS) but the safety of this practice is not well studied. The objective of this study was to assess the safety of using both IV and topical TXA in ESS. A scoping review was performed to investigate the effect of TXA on respiratory epithelia. A retrospective single-surgeon study was used to assess 177 comprehensive ESS cases from January 2017–December 2019 for the safety of combined IV and topical TXA. The scoping review demonstrated that respiratory epithelia could withstand a wide range of TXA concentrations without detrimental morphological effects. Topical TXA may have positive effects on wound healing and inflammation. The retrospective study showed no thromboembolic complications attributable to TXA in the 28 days after ESS. Only two patients (1.3%) who received TXA re-presented with post-operative bleeding. The use of IV and topical TXA is safe with regards to its effect on respiratory epithelium and thromboembolic disease. Topical TXA may have more positive effects than merely the reduction of bleeding following ESS. Full article
(This article belongs to the Special Issue Innovations in the Management of Chronic Rhinosinusitis)
Show Figures

Figure 1

Back to TopTop